ArticleClinical and experimental medicine2019

RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.

Keiji Mashimo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.